The European Rare Kidney Disease Reference Network


Journal Watch

Thrombotic microangiopathies

Long-term outcome of diarrhea-associated hemolytic uremic syndrome is poorly related to markers of kidney injury at 1-year follow-up in a population-based cohort.
Author(s): Monet-Didailler C, Godron-Dubrasquet A, Madden I, Delmas Y, Llanas B, Harambat J
Source: Pediatr Nephrol 2018 Oct 27;
Publication date: 2018-10-27
Emerging Shiga-toxin-producing Escherichia coli serogroup O80 associated hemolytic and uremic syndrome in France, 2013-2016: Differences with other serogroups.
Author(s): Ingelbeen B, Bruyand M, Mariani-Kurkjian P, Le Hello S, Danis K, Sommen C, Bonacorsi S, de Valk H
Source: PLoS One 2018;13(11):e0207492
Publication date: 2018
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.
Author(s): Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ
Source: Pediatr Nephrol 2018 Nov 6;
Publication date: 2018-11-6
Eculizumab and thrombotic microangiopathy after hematopoietic stem cell transplantation: A report on its efficacy and safety in two pediatric patients.
Author(s): Genere L, Bacchetta J, Bertrand Y, Javouhey E, Cheikh N, Sellier-Leclerc AL
Source: Arch Pediatr 2018 Nov;25(8):485-488
Publication date: 2018-11
Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome.
Author(s): Sridharan M, Go RS, Abraham RS, Fervenza FC, Sethi S, Bryant SC, Spears GM, Murray DL, Willrich MAV
Source: Mayo Clin Proc 2018 Oct;93(10):1351-1362
Publication date: 2018-10
+ Show 24 more...